Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 5
Submit an article Journal homepage
34
Views
0
CrossRef citations to date
0
Altmetric
Theme: Interventional Cardiology - Review

Stent thrombosis in patients with chronic kidney disease

Michael Donahue Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples, Italy
&
Carlo Briguori Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples, Italy. [email protected]
Pages 617-626 | Published online: 10 Jan 2014

References

  • Yan BP, Duffy SJ, Clark DJ et al.; Melbourne Interventional Group. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). Am. J. Cardiol. 101(12), 1716–1722 (2008).
  • de la Torre-Hernandez JM, Alfonso F, Hernandez F et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J. Am. Coll. Cardiol. 51(10), 986–990 (2008).
  • Briguori C, Airoldi F, Chieffo A, Carlino M, Montorfano M, Colombo A. Renal function and drug-eluting stent. Int. J. Cardiol. 142(1), 92–94 (2010).
  • Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126–2130 (2005).
  • Tsai TT, Messenger JC, Brennan JM et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry–CMS claims database. J. Am. Coll. Cardiol. 58(18), 1859–1869 (2011).
  • Das P, Moliterno DJ, Charnigo R et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J. Invasive Cardiol. 18(9), 405–408 (2006).
  • Lemos PA, Arampatzis CA, Hoye A et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am. J. Cardiol. 95(2), 167–172 (2005).
  • Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 221–231 (2004).
  • Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113(8), 1108–1113 (2006).
  • Zhu ZB, Zhang RY, Zhang Q et al. Moderate-severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study. Cardiology 112(3), 191–199 (2009).
  • Smits PC, Kedhi E, Royaards KJ et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). J. Am. Coll. Cardiol. 58(1), 11–18 (2011).
  • Stone GW, Rizvi A, Sudhir K et al.; SPIRIT IV Investigators. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J. Am. Coll. Cardiol. 58(1), 19–25 (2011).
  • Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372(9644), 1163–1173 (2008).
  • Holmes DR Jr, Kereiakes DJ, Garg S et al. Stent thrombosis. J. Am. Coll. Cardiol. 56(17), 1357–1365 (2010).
  • Lüscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115(8), 1051–1058 (2007).
  • Machecourt J, Danchin N, Lablanche JM et al.; EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J. Am. Coll. Cardiol. 50(6), 501–508 (2007).
  • Kaya E, Cuneo A, Hochadel M et al. Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents. Clin. Res. Cardiol. 100(12), 1103–1109 (2011).
  • Aoki J, Lansky AJ, Mehran R et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 119(5), 687–698 (2009).
  • Lambert ND, Sacrinty MT, Ketch TR et al. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am. Heart J. 157(4), 688–694 (2009).
  • Planer D, Beyar R, Almagor Y et al. Long-term (>3 years) outcome and predictors of clinical events after insertion of sirolimus-eluting stent in one or more native coronary arteries (from the Israeli arm of the e-Cypher registry). Am. J. Cardiol. 101(7), 953–959 (2008).
  • Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol. 98(3), 352–356 (2006).
  • Wang ZJ, Zhou YJ, Zhao YX, Liu YY, Shi DM. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents. J. Am. Coll. Cardiol. 56, B73 (2010).
  • Kimura T, Morimoto T, Kozuma K et al.; RESTART Investigators. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 122(1), 52–61 (2010).
  • Lasala JM, Cox DA, Dobies D et al.; ARRIVE 1 and ARRIVE 2 Participating Physicians. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ. Cardiovasc. Interv. 2(4), 285–293 (2009).
  • Latif F, Kleiman NS, Cohen DJ et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and IschemicEvents) Registry. J. Am. Coll. Cardiol. Interv. 2, 37–44 (2009).
  • Stone GW, Ellis SG, Cox DA et al.; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109(16), 1942–1947 (2004).
  • Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356(10), 998–1008 (2007).
  • Fajadet J, Morice MC, Bode C et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111(8), 1040–1044 (2005).
  • Moses JW, Leon MB, Popma JJ et al.; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315–1323 (2003).
  • Abdel-Latif A, Mukherjee D, Mesgarzadeh P, Ziada KM. Drug-eluting stents in patients with end-stage renal disease: meta-analysis and systematic review of the literature. Catheter Cardiovasc. Interv. 76(7), 942–948 (2010).
  • Green SM, Selzer F, Mulukutla SR et al. Comparison of bare-metal and drug-eluting stents in patients with chronic kidney disease (from the NHLBI Dynamic Registry). Am. J. Cardiol. 108(11), 1658–1664 (2011).
  • Ichimoto E, Kobayashi Y, Iijima Y, Kuroda N, Kohno Y, Komuro I. Long-term clinical outcomes after sirolimus-eluting stent implantation in dialysis patients. Int. Heart J. 51(2), 92–97 (2010).
  • Kim BK, Oh S, Jeon DW et al.; Korean Multicenter Angioplasty Team (KOMATE) Investigators. Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: results of Korean multicenter angioplasty team (KOMATE) Registry. J. Interv. Cardiol. 22(5), 411–419 (2009).
  • Syed AI, Ben-Dor I, Collins SD et al. Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with chronic renal insufficiency. J. Interv. Cardiol. 23(1), 33–39 (2010).
  • Ishio N, Kobayashi Y, Takebayashi H et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ. J. 71(10), 1525–1529 (2007).
  • Okada T, Hayashi Y, Toyofuku M et al. One-year clinical outcomes of dialysis patients after implantation with sirolimus-eluting coronary stents. Circ. J. 72(9), 1430–1435 (2008).
  • Otsuka Y, Ishiwata S, Inada T et al. Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry. Eur. Heart J. 32(7), 829–837 (2011).
  • Hassani SE, Chu WW, Wolfram RM et al. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. J. Invasive Cardiol. 18(6), 273–277 (2006).
  • Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M. Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb. Res. 83(5), 351–361 (1996).
  • Mezzano D, Tagle R, Panes O et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb. Haemost. 76(3), 312–321 (1996).
  • Mezzano D, Tagle R, Pais E et al. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb. Res. 88(6), 465–472 (1997).
  • Price MJ, Berger PB, Teirstein PS et al.; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097–1105 (2011).
  • Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53(10), 849–856 (2009).
  • Brar SS, ten Berg J, Marcucci R et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J. Am. Coll. Cardiol. 58(19), 1945–1954 (2011).
  • Morel O, El Ghannudi S, Jesel L et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J. Am. Coll. Cardiol. 57(4), 399–408 (2011).
  • Angiolillo DJ, Bernardo E, Capodanno D et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J. Am. Coll. Cardiol. 55(11), 1139–1146 (2010).
  • Best PJ, Steinhubl SR, Berger PB et al.; CREDO Investigators. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am. Heart J. 155(4), 687–693 (2008).
  • Fox KA, Mehta SR, Peters R et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110, 1202–1208 (2004).
  • Dasgupta A, Steinhubl SR, Bhatt DL et al.; CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am. J. Cardiol. 103(10), 1359–1363 (2009).
  • Stam F, van Guldener C, Becker A et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J. Am. Soc. Nephrol. 17(2), 537–545 (2006).
  • Landray MJ, Wheeler DC, Lip GY et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am. J. Kidney Dis. 43(2), 244–253 (2004).
  • Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100(25), 2473–2476 (1999).
  • Shimabukuro M, Higa N, Asahi T et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J. Clin. Endocrinol. Metab. 88(7), 3236–3240 (2003).
  • Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193–202 (2006).
  • Stenvinkel P. Chronic low-grade inflammation in chronic kidney disease. Presented at: The 39th American Society of Nephrology Annual Meeting. San Diego, CA, USA, 14–19 November 2006.
  • Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ. Res. 89(9), 763–771 (2001).
  • Park DW, Yun SC, Lee JY et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 120(20), 1987–1995 (2009).
  • Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am. J. Kidney Dis. 37(3), 484–489 (2001).
  • Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K, Bhatt DL; REACH Registry Investigators. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am. Heart J. 158(1), 141–148.e1 (2009).
  • Stefanini GG, Serruys PW, Silber S et al. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J. Am. Coll. Cardiol. 57(22), 2221–2232 (2011).
  • Gruberg L, Jeremias A, Rutledge DR et al. Clinical outcomes in real-world patients receiving the XIENCE V® everolimus-eluting stent presenting with chronic kidney disease: one-year results from the XIENCE V USA study. J. Am. Coll. Cardiol. 57, E1896 (2011).
  • Toutouzas K, Patsa C, Synetos A et al. The impact of new generation drug-eluting stent implantation on patients with chronic kidney disease and a single lesion in the proximal segment of the left anterior descending artery. Hellenic J. Cardiol. 52(2), 103–110 (2011).
  • Sakakibara T, Ishii H, Toriyama T et al. Sirolimus-eluting stent vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis. Circ. J. 76(2), 351–355 (2012).
  • James S, Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122(11), 1056–1067 (2010).
  • Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
  • Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  • Mehran R, Nikolsky E, Lansky AJ et al. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. JACC Cardiovasc. Interv. 2(8), 748–757 (2009).
  • Saltzman AJ, Stone GW, Claessen BE et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc. Interv. 4(9), 1011–1019 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.